TET2 mutations appear particularly promiscuous, as they have been shown to be associated with CHIP in healthy older adults; myeloid malignancies including acute myeloid leukemia (AML), myeloproliferative neoplasms (MPNs), and myelodysplastic/myeloproliferative neoplasms (MDS/MPNs); and a variety of mature B-cell and T-cell non-Hodgkin lymphomas. This evidence concerns the gene TET2 and myeloproliferative disorder.